Transforming the way we protect those who protect us.
The NCBiotech Bio Defense program expands the life science base of North Carolina’s $38 billion defense economy.
Our Bio Defense outreach goes far beyond concerns over bioterrorism. NCBiotech and partners -- North Carolina’s small companies, researchers and military representatives -- are thinking more broadly. We work to provide vaccines for soldiers, to protect the food supply, and to find how best to deploy novel technologies that will protect our soldiers and heal those who sustain wounds in battle.
Information on North Carolina's Bio Defense companies in North Carolina can be found in the NCBiotech Company Directory.
Given the size and significance of the federal investments in NC, NCBiotech and partners are working to bring the state’s innovative, life science technological expertise to bear to address critical challenges faced by the military and national security agencies. Developing strategies to better align the state’s well-recognized life science strengths with the Department of Defense (DoD) and national security strategic priorities will enable our state to be a critical solution provider on challenging problems while also increasing defense funding to support North Carolina researchers and companies.
Some of these NCBiotech-led activities include:
Providing support for university-based researchers and small businesses that have a technology that addresses a need in the Bio Defense arena and educate and support their efforts in seeking DoD or homeland security relationships and funding
Promoting and representing North Carolina at targeted military and federal Bio Defense conferences throughout the United States and promote our state's life science capabilities
Hosting or sponsoring conferences where military, government, academic and industry experts can network and collaborate
Connecting military, industry and academia partners to promote North Carolina’s Bio Defense capabilities at the state and federal level
For additional information, please see our Bio Defense Initiative one-pager.
Biomedical Advanced Research & Development Authority (BARDA)
For future BARDA DRIVe opportunities, sign up for the listserv.
If you or your company are developing a medical countermeasure or platform technology to combat chemical, biological, radiological, or nuclear threats, pandemic influenza or other emerging infectious diseases, you can get insights and strategic advice from HHS/ASPR Biomedical Advanced Research and Development Authority (BARDA) at a TechWatch meeting.
BARDA TechWatch meetings are your chance to introduce your proposed solution that may meet one or more of BARDA’s current priorities, and are the beginning of an important dialogue.
TechWatch meetings can be a good way in which to also get insights from other professionals from other governmental agencies with related portfolios. They can take several weeks to a couple of months to schedule so take that into consideration in your planning.
BARDA DRIVe Industry Day 2018 Presentations
BARDA remains committed to engaging industry and government partners to fulfill their mission, saving lives and protecting Americans through the research and development of medical countermeasures against serious health security threats.
The theme of BARDA Industry Day 2018 held October 29-30, 2018 in Washington, DC was "Driving Innovation." Copies of the presentations are now available online for review.
Presentations from the DRIVe Session on October 30 at 1:00 p.m. are also available below.
View the Latest Updates From BARDA
Combat Antibiotic Resistant Bacteria (CARB-X)
Application for CARB-X Funding Round 4 is now open:
- Direct-acting small molecule antibiotics: Funding Round 4 will be open for Expressions of Interest November 12 through November 19, 2019, 5 PM ET. The scope of Round 4 is restricted to new classes of antibiotics and/or new targets for therapeutics.
You can find all the information you need at https://carb-x.org/apply/. Please review the information in the sections under the Apply tab.
Please read the scope of each round carefully at https://carb-x.org/apply/what-carb-x-funds/, and note the timing that is relevant to your project.
BARDA Division of Research, Innovation and Ventures (DRIVe)
UPDATE: SUBMISSIONS CLOSED ON MAY 28TH. Per an announcement on FedBizOpps, abstract acceptance is temporarily on hold due to a lack of available funding.
Apply now! DRIVe's new EZ-BAA application is streamlined, fast and user-friendly.
The North Carolina Biotechnology Center is pleased to announce the Biomedical Advanced Research and Development Authority (BARDA) Division of Research, Innovation and Ventures (DRIVe) simplified application process, called the EZ BAA, is now open for business. Medical product developers, research teams, and companies offering disruptive solutions to health security threats are invited to submit abstracts beginning today using this simplified EZ BAA process.
BARDA is looking for the most innovative products and technologies to protect Americans from the most serious systemic, natural and intentional health security threats. Our goal is to build a portfolio of products representing disruptive innovative approaches that will transform health security.
Applications accepted through this streamlined process must offer transformative innovation, products and technologies to protect Americans from health security threats. This application process is a business-friendly simple abstract.
In-scope priority areas include: products and solutions to reduce illness and death from sepsis as part of DRIVe’s Solving Sepsis initiative; technologies and processes to identify infections and exposures to biological and other health threats, as outlined in the Early Notification to Act, Control, and Treat (ENACT) initiative; and tools and techniques to mitigate the damages and loss of life associated with catastrophic events.
Applying is simple:
- Download the application form from the website.
- Submit a technical abstract no longer than 2,000 words.
- Include a cost proposal of an additional 2,000 words or less.
- Proposed costs should not exceed $749,000.
What happens next:
- Once submitted, DRIVe’s experts will review the application to ensure it is within scope and meets DRIVe criteria.
- As the applicant, you’ll be notified of the review results within 30 days of your submission.
Learn more about the DRIVe EZ-BAA review criteria.
For more information, visit the DRIVe website.
Have questions? Looking for more information? Contact DRIVeContracting@hhs.gov
Emil Runge, Program Manager
Mobile: (404) 668-2136
First Flight Health Security Accelerator
2 Davis Drive, Research Triangle Park, NC
Medical Technology Enterprise Consortium (MTEC)
The Medical Technology Enterprise Consortium (MTEC) is excited to post this announcement for a Request for Project Information (RPI) focused on Traumatic Brain Injury Drug Treatment (TBI DT) - to rapidly conduct Phase 2 clinical trials on traumatic brain injury (TBI) drug candidates and identify at least one TBI drug candidate for advancement into a Phase 3 clinical trial. The end goal of the TBI DT program is a commercially-available TBI drug that is approved by the U.S. Food and Drug Administration (FDA) to treat moderate to severe TBI (i.e., patients presenting with a Glasgow Coma Scale (GCS) score of =12, or 13-15 with evidence of intracranial injury on imaging (CT or MRI) referable to trauma).
Additional information on this RPI, including background material and guidance for the preparation of Project Information Papers to MTEC, can be found here: https://www.fbo.gov/spg/USA/USAMRAA/DAMD17/MTEC-19-11-TBI-DT/listing.html
For inquiries regarding this announcement, please direct your correspondence to the following contacts:
Technical questions and Membership questions
Dr. Lauren Palestrini, MTEC Director of Research, Lauren.Palestrini@officer.mtec-sc.org
Ms. Kathy Zolman, MTEC Interim Executive Director, Kathy.firstname.lastname@example.org
United States Army Medical and Materiel Command (USAMRMC)
The United States Army Medical and Materiel Command's (USAMRMC) mission is to provide solutions to medical problems of importance to the American Service member at home and abroad, as well as to the general public at large. Extramural research and development programs play a vital role in the fulfillment of the objectives established by the USAMRMC.
The FY18-FY22 USAMRMC Broad Agency Announcement (BAA) is intended to solicit extramural research and development ideas. Research and development funded through the BAA are intended and expected to benefit and inform both military and civilian medical practice and knowledge.
Read more information.